Riarify (previously CHF 5993 Chiesi Farmaceutici S.p.A.)

Nazione: Unione Europea

Lingua: inglese

Fonte: EMA (European Medicines Agency)

Principio attivo:

formoterol fumarate dihydrate, glycopyrronium, Beclometasone dipropionate

Commercializzato da:

Chiesi Farmaceutici S.p.A.

Codice ATC:

R03AL09

INN (Nome Internazionale):

beclometasone, formoterol

Gruppo terapeutico:

Drugs for obstructive airway diseases,

Area terapeutica:

Pulmonary Disease, Chronic Obstructive

Indicazioni terapeutiche:

Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist (for effects on symptoms control and prevention of exacerbations see section 5.1).

Dettagli prodotto:

Revision: 4

Stato dell'autorizzazione:

Authorised

Data dell'autorizzazione:

2018-04-23

Foglio illustrativo

34
B. PACKAGE LEAFLET
35
PACKAGE LEAFLET: INFORMATION FOR THE USER
RIARIFY 87 MICROGRAMS/5 MICROGRAMS/9 MICROGRAMS PRESSURISED
INHALATION, SOLUTION
beclometasone dipropionate/formoterol fumarate
dihydrate/glycopyrronium
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Riarify is and what it is used for
2.
What you need to know before you use Riarify
3.
How to use Riarify
4.
Possible side effects
5.
How to store Riarify
6.
Contents of the pack and other information
1.
WHAT RIARIFY IS AND WHAT IT IS USED FOR
Riarify is a medicine to help breathing that contains the three active
substances:
•
beclometasone dipropionate,
•
formoterol fumarate dihydrate and
•
glycopyrronium.
Beclometasone dipropionate belongs to a group of medicines called
corticosteroids which act to
reduce the swelling and irritation in your lungs.
Formoterol and glycopyrronium are medicines called long-acting
bronchodilators. They act in
different ways to relax the muscles in your airways, helping to open
the airways wider and allowing
you to breathe more easily.
Regular treatment with these three active substances helps to relieve
and prevent symptoms such as
shortness of breath, wheezing and cough in adult patients with chronic
obstructive pulmonary disease
(COPD). Riarify can reduce exacerbations (flare-ups) of COPD symptoms
.
COPD is a serious long-
term disease in which the airways become blocked and air sacs inside
the lungs become damaged,
leading to difficulty breathing.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE RIARIFY
D

Scheda tecnica

1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Riarify 87 micrograms/5 micrograms/9 micrograms pressurised
inhalation, solution
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each delivered dose (the dose leaving the mouthpiece) contains 87
micrograms of beclometasone
dipropionate, 5 micrograms of formoterol fumarate dihydrate and 9
micrograms of glycopyrronium (as
11 micrograms glycopyrronium bromide).
Each metered dose (the dose leaving the valve) contains 100 micrograms
of beclometasone
dipropionate, 6 micrograms of formoterol fumarate dihydrate and 10
micrograms of glycopyrronium
(as 12.5 micrograms glycopyrronium bromide).
Excipient with known effect
Riarify contains 8.856 mg ethanol per actuation.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Pressurised inhalation, solution (pressurised inhalation)
Colourless to yellowish liquid solution.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Maintenance treatment in adult patients with moderate to severe
chronic obstructive pulmonary
disease (COPD) who are not adequately treated by a combination of an
inhaled corticosteroid and a
long-acting beta2-agonist or a combination of a long-acting
beta2-agonist and a long-acting
muscarinic antagonist (for effects on symptoms control and prevention
of exacerbations see
section 5.1).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The recommended dose is two inhalations twice daily.
The maximum dose is two inhalations twice daily.
Special populations
_ _
_Elderly _
No dosage adjustment is required in elderly patients (65 years of age
and older).
_ _
_Renal impairment _
Riarify can be used at the recommended dose in patients with mild
(glomerular filtration rate [GFR]
≥50 to <80 mL/min/1.73 m
2
) to moderate (GFR ≥30 to <50 mL/min/1.73 m
2
) renal impairment. Use in
patients with severe (GFR <30 mL/min/1.73 m
2
) renal impairment or end-stage renal (GFR
<15 mL/min/1.73 m
2
) disease requiring dialysis, especially if associated with
significant body weight
3